Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

Yang Li, Lihua Zou, Qiyuan Li, Benjamin Haibe-Kains, Ruiyang Tian, Yan Le, Christine Desmedt, Christos Sotiriou, Zoltan Szallasi, J. Dirk Iglehart, Andrea Richardson, Zhigang Charles Wang

Research output: Contribution to journalArticle

Abstract

Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates. However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes. By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. We confirmed the association in an analysis of multiple independent cohorts. SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. Overexpression of LAPTM4B resulted in sequestration of the anthracycline doxorubicin, delaying its appearance in the nucleus. Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. Our results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence. Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy.

Original languageEnglish (US)
Pages (from-to)214-218
Number of pages5
JournalNature Medicine
Volume16
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Chemotherapy
Anthracyclines
Amplification
Genes
Breast Neoplasms
Recurrence
Drug Therapy
Tumors
Adjuvant Chemotherapy
Neoplasms
Chromosomes
Genomics
Doxorubicin
Surgery
Cells
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Le, Y., ... Wang, Z. C. (2010). Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nature Medicine, 16(2), 214-218. https://doi.org/10.1038/nm.2090

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. / Li, Yang; Zou, Lihua; Li, Qiyuan; Haibe-Kains, Benjamin; Tian, Ruiyang; Le, Yan; Desmedt, Christine; Sotiriou, Christos; Szallasi, Zoltan; Iglehart, J. Dirk; Richardson, Andrea; Wang, Zhigang Charles.

In: Nature Medicine, Vol. 16, No. 2, 02.2010, p. 214-218.

Research output: Contribution to journalArticle

Li, Y, Zou, L, Li, Q, Haibe-Kains, B, Tian, R, Le, Y, Desmedt, C, Sotiriou, C, Szallasi, Z, Iglehart, JD, Richardson, A & Wang, ZC 2010, 'Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer', Nature Medicine, vol. 16, no. 2, pp. 214-218. https://doi.org/10.1038/nm.2090
Li, Yang ; Zou, Lihua ; Li, Qiyuan ; Haibe-Kains, Benjamin ; Tian, Ruiyang ; Le, Yan ; Desmedt, Christine ; Sotiriou, Christos ; Szallasi, Zoltan ; Iglehart, J. Dirk ; Richardson, Andrea ; Wang, Zhigang Charles. / Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. In: Nature Medicine. 2010 ; Vol. 16, No. 2. pp. 214-218.
@article{38385dbcbb954d52b57bca2492ce4ee9,
title = "Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer",
abstract = "Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates. However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes. By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. We confirmed the association in an analysis of multiple independent cohorts. SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. Overexpression of LAPTM4B resulted in sequestration of the anthracycline doxorubicin, delaying its appearance in the nucleus. Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. Our results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence. Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy.",
author = "Yang Li and Lihua Zou and Qiyuan Li and Benjamin Haibe-Kains and Ruiyang Tian and Yan Le and Christine Desmedt and Christos Sotiriou and Zoltan Szallasi and Iglehart, {J. Dirk} and Andrea Richardson and Wang, {Zhigang Charles}",
year = "2010",
month = "2",
doi = "10.1038/nm.2090",
language = "English (US)",
volume = "16",
pages = "214--218",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

AU - Li, Yang

AU - Zou, Lihua

AU - Li, Qiyuan

AU - Haibe-Kains, Benjamin

AU - Tian, Ruiyang

AU - Le, Yan

AU - Desmedt, Christine

AU - Sotiriou, Christos

AU - Szallasi, Zoltan

AU - Iglehart, J. Dirk

AU - Richardson, Andrea

AU - Wang, Zhigang Charles

PY - 2010/2

Y1 - 2010/2

N2 - Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates. However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes. By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. We confirmed the association in an analysis of multiple independent cohorts. SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. Overexpression of LAPTM4B resulted in sequestration of the anthracycline doxorubicin, delaying its appearance in the nucleus. Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. Our results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence. Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy.

AB - Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates. However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes. By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. We confirmed the association in an analysis of multiple independent cohorts. SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. Overexpression of LAPTM4B resulted in sequestration of the anthracycline doxorubicin, delaying its appearance in the nucleus. Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. Our results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence. Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=76349095348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349095348&partnerID=8YFLogxK

U2 - 10.1038/nm.2090

DO - 10.1038/nm.2090

M3 - Article

C2 - 20098429

AN - SCOPUS:76349095348

VL - 16

SP - 214

EP - 218

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -